Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) announced that its proprietary nasal spray influenza ...

A new nasal spray vaccine for H5N1 bird flu has shown promising early results, raising hopes it could one day be used to help ...

CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine at the World Government Summit 2026 (WGS 2026) which convened from ...

French drug company Sanofi announced it's discontinuing research and development for its next-generation mRNA flu vaccine.

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while holding the potential to provide up to $500 million more in development and ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.

The FDA plans to tighten vaccine approval standards, requiring more evidence of safety and efficacy. Georgia doctors warn the move could discourage vaccination and reduce vaccine development. The ...

A Nipah virus vaccine developed by the University of Tokyo is set to begin Phase 1 human trials in April, offering hope ...

(Yicai) Feb. 9 -- Kangtai Biological Products said it has terminated the Chinese vaccine maker's plan to establish a joint ...